Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Correlazione della PET/CT con FDG precoce e del ctDNA nei pazienti con melanoma trattati con inibitori del checkpoint immunitario (ICI)

11 novembre 2026 aggiornato da: University of Wisconsin, Madison

Correlazione tra tomografia a emissione di positroni/tomografia computerizzata (PET/CT) a intervallo precoce con 18F-fluorodesossiglucosio e DNA tumorale circolante (ctDNA) in pazienti con melanoma avanzato trattati con inibitori del checkpoint immunitario

The purpose of this research study is to determine if analysis of PET/CT scans and testing of blood samples in people with melanoma that has spread in their body can help researchers determine which patients are more or less likely to respond to immunotherapy and are more or less likely to have side effects. 24 participants will be enrolled and be on study until approximately 4 weeks after their first dose of Immune Checkpoint Inhibitor therapy.

Panoramica dello studio

Descrizione dettagliata

This is a pilot, prospective, observational study to estimate the degree to which baseline and early interval 18F-FDG PET/CT imaging within 3-4 weeks of ICI therapy initiation can accurately correlate with ctDNA level trends, predict clinical response, onset of immune-related adverse events, and survival outcomes in advanced stage melanoma patients.

Primary Objective

• To determine if early interval response assessment with 18F-FDG PET/CT during initial treatment with ICI therapy at 3-4 weeks correlates with ctDNA level changes in advanced melanoma patients.

Secondary Objectives

  • To determine if early interval response assessment with 18F-FDG PET/CT during initial treatment with ICI therapy at 3-4 weeks predicts clinical efficacy at standard disease assessment time points in advanced melanoma patients.
  • To assess if early interval response assessment with 18F-FDG PET/CT predicts development of clinical irAEs in advanced melanoma patients.
  • To assess if early interval response assessment with 18F-FDG PET/CT and ctDNA level predicts progression-free survival (PFS) in advanced melanoma patients.
  • To assess if early interval response assessment with 18F-FDG PET/CT and ctDNA level predicts overall survival (OS) in advanced melanoma patients.

Tipo di studio

Osservativo

Iscrizione (Effettivo)

25

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Wisconsin
      • Madison, Wisconsin, Stati Uniti, 53792
        • University of Wisconsin Hospitals and Clinics (UWHC)

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

24 participants with advanced stage III or stage IV melanoma with measurable disease who are deemed appropriate for treatment with ICI therapy.

Descrizione

Inclusion Criteria:

  • Willing to provide informed consent.
  • Must have an advanced stage III or stage IV melanoma diagnosis for which treatment with ipilimumab, nivolumab, and/or pembrolizumab, either alone or in combination with other ICI therapy, is planned.
  • Must be planning to participate in Signatera™ (ctDNA level) monitoring with standard of care laboratory testing routinely obtained for treatment with ICI therapy.
  • Individuals at least 18 years of age.
  • Women of childbearing potential must be willing to use effective contraception as discussed with their oncologist while participating in this study.
  • Willing to comply with all study procedures and be available for the duration of the study.

Exclusion Criteria:

  • Not able to receive treatment with ICI therapy
  • Use of investigational drugs, biologics, or devices within 30 days prior to enrollment.
  • Women who are pregnant, lactating, or planning on becoming pregnant during the study.
  • Not suitable for study participation due to other reasons at the discretion of the investigators.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Modelli osservazionali: COHORT
  • Prospettive temporali: PROSPECTIVE

Coorti e interventi

Gruppo / Coorte
Intervento / Trattamento
Pazienti con melanoma avanzato con inibitori del checkpoint immunitario

research scan 3-4 weeks after start of immunotherapy

Altri nomi:
  • 18F-FDG ANIMALE DOMESTICO/TAC

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in ctDNA level from baseline to 3-4 week after the start of therapy
Lasso di tempo: baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)

ctDNA level is monitored per standard of care in this population, data from chart review.

baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
Change in 18F-FDG PET/CT response from baseline to 3-4 week after the start of therapy
Lasso di tempo: baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)

Lesion-level and patient-level 18F-FDG PET/CT response assessment at baseline and at 3-4 weeks after starting ICI therapy reported as SUV max.

baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
Correlation between ctDNA level change and 18F-FDG PET/CT response from baseline to 3-4 week after the start of therapy
Lasso di tempo: baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)

Correlate lesion-level and patient-level 18F-FDG PET/CT response assessment at baseline and at 3-4 weeks after starting ICI therapy with quantitative changes in ctDNA levels at baseline and at 3-4 weeks after starting ICI therapy. Pearson's or Rank's correlation coefficient will be used to measure the baseline measures for ctDNA level trends and PET/CT responses and for those measurements at 3-4 weeks.

baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
Diagnostic Accuracy of ctDNA level trend and PET/CT imaging for predicting growth inhibition as measured by Area under the Curve
Lasso di tempo: baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)

Receiver-operator curve analysis will be performed to determine the diagnostic accuracy of ctDNA level trend and PET/CT imaging for predicting growth inhibition (area under the curve).

baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Objective Response Rate (ORR)
Lasso di tempo: up to 12 months after the first ICI dose (approximately 1 year on study)

Correlate lesion-level and patient-level 18F-FDG PET/CT treatment response assessment at baseline and at 3-4 weeks after starting ICI therapy with clinical response evaluations (RECIST, PERCIST, PECRIT, iRECIST, irRECIST) at 3, 6, 9, and 12 months after the first ICI dose. ORR is Partial Response (PR) plus Complete Response (CR).

up to 12 months after the first ICI dose (approximately 1 year on study)
Disease Control Rate (DCR)
Lasso di tempo: up to 12 months after the first ICI dose (approximately 1 year on study)

Correlate lesion-level and patient-level 18F-FDG PET/CT treatment response assessment at baseline and at 3-4 weeks after starting ICI therapy with clinical response evaluations (RECIST, PERCIST, PECRIT, iRECIST, irRECIST) at 3, 6, 9, and 12 months after the first ICI dose. DCR is Stable Disease (SD) plus PR plus CR.

up to 12 months after the first ICI dose (approximately 1 year on study)
Change in Standard Uptake Value (SUV) metrics with onset of Immune Related Adverse Events (irAE)
Lasso di tempo: up to 12 months after the first ICI dose (approximately 1 year on study)

Correlate organ-level FDG uptake and changes from the baseline and early 18F-FDG PET/CT assessment with onset of first, second, and third symptomatic irAE per CTCAE v5.0

up to 12 months after the first ICI dose (approximately 1 year on study)
Progression Free Survival (PFS)
Lasso di tempo: up to 3 years after the first ICI dose (approximately 3 years on study)

PFS will be summarized using Kaplan-Meier estimates of the median survival times. Point estimates as well as 95% confidence intervals will be provided

up to 3 years after the first ICI dose (approximately 3 years on study)
Correlation Coefficient for 18F-FDG PET/CT response at 3-4 weeks after the start of therapy and PFS
Lasso di tempo: up to 3 years after the first ICI dose (approximately 3 years on study)

Correlate early 18F-FDG PET/CT treatment response with Progression Free Survival (PFS) as measured from the date of initiation of ICI treatment until the criteria for disease progression is met as defined by RECIST, PECRIT, or death occurs.

up to 3 years after the first ICI dose (approximately 3 years on study)
Correlation Coefficient for ctDNA level at 3-4 weeks after the start of therapy and PFS
Lasso di tempo: up to 3 years after the first ICI dose (approximately 3 years on study)

Correlate early ctDNA level trends with Progression Free Survival (PFS) as measured from the date of initiation of ICI treatment until the criteria for disease progression is met as defined by RECIST, PECRIT, or death occurs.

up to 3 years after the first ICI dose (approximately 3 years on study)
Overall Survival (OS)
Lasso di tempo: up to 3 years after the first ICI dose (approximately 3 years on study)

OS will be summarized using Kaplan-Meier estimates of the median survival times. Point estimates as well as 95% confidence intervals will be provided

up to 3 years after the first ICI dose (approximately 3 years on study)
Correlation Coefficient for 18F-FDG PET/CT response at 3-4 weeks after the start of therapy and OS
Lasso di tempo: up to 3 years after the first ICI dose (approximately 3 years on study)

Correlate early 18F-FDG PET/CT response assessment with Overall Survival (OS) as measured from the date of initiation of ICI treatment until date of death from any cause.

up to 3 years after the first ICI dose (approximately 3 years on study)
Correlation Coefficient for ctDNA level at 3-4 weeks after the start of therapy and OS
Lasso di tempo: up to 3 years after the first ICI dose (approximately 3 years on study)

Correlate early ctDNA level trends with Overall Survival (OS) as measured from the date of initiation of ICI treatment until date of death from any cause.

up to 3 years after the first ICI dose (approximately 3 years on study)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Vincent Ma, MD, University of Wisconsin, Madison

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

30 gennaio 2024

Completamento primario (Stimato)

1 gennaio 2027

Completamento dello studio (Stimato)

1 gennaio 2029

Date di iscrizione allo studio

Primo inviato

27 dicembre 2023

Primo inviato che soddisfa i criteri di controllo qualità

27 dicembre 2023

Primo Inserito (Effettivo)

10 gennaio 2024

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

16 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

11 novembre 2026

Ultimo verificato

1 gennaio 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi